High-Flow Humidified Oxygen as an Early Intervention in Children With Acute Severe Asthma : Protocol for a Feasibility Randomized Controlled Trial
©Hector Rojas-Anaya, Akshat Kapur, Graham Roberts, Damian Roland, Atul Gupta, Michaela Lazner, Jane Bayreuther, John Pappachan, Christina Jones, Stephen Bremner, Fleur Cantle, Paul Seddon. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 28.03.2024..
BACKGROUND: Acute severe asthma (ASA) is a leading cause of hospital attendance in children. Standard first-line therapy consists of high-dose inhaled bronchodilators plus oral corticosteroids. Treatment for children who fail to respond to first-line therapy is problematic: the use of intravenous agents is inconsistent, and side effects are frequent. High-flow humidified oxygen (HiFlo) is widely used in respiratory conditions and is increasingly being used in ASA, but with little evidence for its effectiveness. A well-designed, adequately powered randomized controlled trial (RCT) of HiFlo therapy in ASA is urgently needed, and feasibility data are required to plan such an RCT. In this study, we describe the protocol for a feasibility study designed to fill this knowledge gap.
OBJECTIVE: This study aims to establish whether a full RCT of early HiFlo therapy in children with ASA can be conducted successfully and safely, to establish whether recruitment using deferred consent is practicable, and to define appropriate outcome measures and sample sizes for a definitive RCT. The underlying hypothesis is that early HiFlo therapy in ASA will reduce the need for more invasive treatments, allow faster recovery and discharge from hospital, and in both these ways reduce distress to children and their families.
METHODS: We conducted a feasibility RCT with deferred consent to assess the use of early HiFlo therapy in children aged 2 to 11 years with acute severe wheeze not responding to burst therapy (ie, high-dose inhaled salbutamol with or without ipratropium). Children with a Preschool Respiratory Assessment Measure score ≥5 after burst therapy were randomized to commence HiFlo therapy or follow standard care. The candidate primary outcomes assessed were treatment failure requiring escalation and time to meet hospital discharge criteria. Patient and parent experiences were also assessed using questionnaires and telephone interviews.
RESULTS: The trial was opened to recruitment in February 2020 but was paused for 15 months owing to the COVID-19 pandemic. The trial was reopened at the lead site in July 2021 and opened at the other 3 sites from August to December 2022. Recruitment was completed in June 2023.
CONCLUSIONS: This feasibility RCT of early HiFlo therapy in children with ASA recruited to the target despite major disturbances owing to the COVID-19 pandemic. The data are currently being analyzed and will be published separately.
TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number Registry ISRCTN78297040; https://www.isrctn.com/ISRCTN78297040.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54081.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
JMIR research protocols - 13(2024) vom: 28. März, Seite e54081 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rojas-Anaya, Hector [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asthma |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2196/54081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370362691 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370362691 | ||
| 003 | DE-627 | ||
| 005 | 20240425233343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2196/54081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370362691 | ||
| 035 | |a (NLM)38546733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rojas-Anaya, Hector |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-Flow Humidified Oxygen as an Early Intervention in Children With Acute Severe Asthma |b Protocol for a Feasibility Randomized Controlled Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©Hector Rojas-Anaya, Akshat Kapur, Graham Roberts, Damian Roland, Atul Gupta, Michaela Lazner, Jane Bayreuther, John Pappachan, Christina Jones, Stephen Bremner, Fleur Cantle, Paul Seddon. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 28.03.2024. | ||
| 520 | |a BACKGROUND: Acute severe asthma (ASA) is a leading cause of hospital attendance in children. Standard first-line therapy consists of high-dose inhaled bronchodilators plus oral corticosteroids. Treatment for children who fail to respond to first-line therapy is problematic: the use of intravenous agents is inconsistent, and side effects are frequent. High-flow humidified oxygen (HiFlo) is widely used in respiratory conditions and is increasingly being used in ASA, but with little evidence for its effectiveness. A well-designed, adequately powered randomized controlled trial (RCT) of HiFlo therapy in ASA is urgently needed, and feasibility data are required to plan such an RCT. In this study, we describe the protocol for a feasibility study designed to fill this knowledge gap | ||
| 520 | |a OBJECTIVE: This study aims to establish whether a full RCT of early HiFlo therapy in children with ASA can be conducted successfully and safely, to establish whether recruitment using deferred consent is practicable, and to define appropriate outcome measures and sample sizes for a definitive RCT. The underlying hypothesis is that early HiFlo therapy in ASA will reduce the need for more invasive treatments, allow faster recovery and discharge from hospital, and in both these ways reduce distress to children and their families | ||
| 520 | |a METHODS: We conducted a feasibility RCT with deferred consent to assess the use of early HiFlo therapy in children aged 2 to 11 years with acute severe wheeze not responding to burst therapy (ie, high-dose inhaled salbutamol with or without ipratropium). Children with a Preschool Respiratory Assessment Measure score ≥5 after burst therapy were randomized to commence HiFlo therapy or follow standard care. The candidate primary outcomes assessed were treatment failure requiring escalation and time to meet hospital discharge criteria. Patient and parent experiences were also assessed using questionnaires and telephone interviews | ||
| 520 | |a RESULTS: The trial was opened to recruitment in February 2020 but was paused for 15 months owing to the COVID-19 pandemic. The trial was reopened at the lead site in July 2021 and opened at the other 3 sites from August to December 2022. Recruitment was completed in June 2023 | ||
| 520 | |a CONCLUSIONS: This feasibility RCT of early HiFlo therapy in children with ASA recruited to the target despite major disturbances owing to the COVID-19 pandemic. The data are currently being analyzed and will be published separately | ||
| 520 | |a TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number Registry ISRCTN78297040; https://www.isrctn.com/ISRCTN78297040 | ||
| 520 | |a INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54081 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a child | |
| 650 | 4 | |a high-flow humidified oxygen therapy | |
| 650 | 4 | |a oxygen therapy | |
| 650 | 4 | |a wheezing | |
| 700 | 1 | |a Kapur, Akshat |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Roland, Damian |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Lazner, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Bayreuther, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Pappachan, John |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Bremner, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Cantle, Fleur |e verfasserin |4 aut | |
| 700 | 1 | |a Seddon, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JMIR research protocols |d 2012 |g 13(2024) vom: 28. März, Seite e54081 |w (DE-627)NLM226893626 |x 1929-0748 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g day:28 |g month:03 |g pages:e54081 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2196/54081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |b 28 |c 03 |h e54081 | ||